// App-Quantinova.ai

5399 : The NSD2 p.E1099K mutation is enriched at relapse and confers drug resistance in a cell context dependent manner in pediatric acute lymphoblastic leukemia

Researchers

Presenter

  • Joanna Pierro

Principal Investigators

  • Jason Saliba

  • Sonali Narang

  • Gunjan Sethia

  • Shella Saint Fleur-Lominy

  • Ashfiyah Chowdhury

  • Takaya Moriyama

  • Kjeld Schmiegelow

  • Jun J. Yang

  • Mignon L. Loh

  • Patrick A. Brown

  • Jinghui Zhang

  • Xiaotu Ma

  • Aristotelis Tsirigos

  • Nikki A. Evensen

  • William L. Carroll

Medical Centers

  • New York University, New York, NY

  • St. Jude Children's Research Hospital, Memphis, TN

  • University Hospital of Copenhagen Rigshospitalet, Copenhagen, Denmark

  • UCSF Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

Locations

  • United States

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved